PharmaTelevision - Moving forward: NovaBay's present and future plans for its compounds

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Moving forward: NovaBay's present and future plans for its compounds

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this interview, filmed at BioPharm in San Francisco, Dr Fintan Walton speaks with Ron Najafi, Chief Executive Officer at NovaBay Pharmaceuticals, a product development firm targeting infections in hopstials and the community

They discuss:

• NovaBay's background as a company
• the fields in which NovaBay operates and its common compounds
• the application of NovaBay's new technologies
• reducing infections in hospitals
• how 2009 has been a positive year for the company
• innovation and Genentech’s involvement in adopting new breakthrough therapeutic approaches
• alliances and getting new products to market

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

NovaBay's background as a company.

Fintan Walton:

Hello and welcome to PharmaTelevision news review here in San Francisco at BioPharm America. On this show I have Dr Ron Najafi, who is Chairman and CEO of NovaBay Pharmaceuticals based in Emeryville here in the Bay Area. Welcome to the show.

Ron Najafi:

Thank you.

Fintan Walton:

Ron Najafi, NovaBay is a novel company in the sense that it's focused on anti-infectives but with a different twist to the normal antibiotic approach that pharmaceuticals companies have taken in the past, your company has done deals and are continuing to do deals. So tell me a little bit more about NovaBay, and how was founded and how you are focused on the anti-infective area?

Ron Najafi:

Sure. So we you are aware of the drug resistant problem that we have pretty much with all of our 150 antibiotics that are available to our doctors in the hospitals. We believe the future is going to have a mix of different technologies and we're going to have a product that does not give rise to resistance, which is based on the variation on compounds generated within white blood cells, these are novel chemical entities that are invented at NovaBay's several years ago.

Fintan Walton:

Okay.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Ron Najafi

Chairman and Chief Executive Officer

Ron Najafi is the founder and Chairman of NovaBay. He has served as President since July 2002, and as Chief Executive Officer since November 2004. Previously, Dr. Ron Najafi served in various management positions within NovaBay including as Chief Scientific Officer. Prior to founding NovaBay, Dr. Ron Najafi was the President and CEO of California Pacific Labs, Inc., a chemical laboratory safety devices company. He has also held scientific roles at Rhone Poulenc Rorer (now Sanofi-Aventis), Applied Biosystems, a division of PerkinElmer, Inc., and Aldrich Chemical. Dr. Ron Najafi received a B.S. and M.S. degree in Chemistry from the University of San Francisco and a Ph.D. in Organic Chemistry from the University of California at Davis.

NovaBay

NovaBay is focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and community environments. Many of these infections have become increasingly difficult to treat because of the rapid increase in infectious microbes that have become resistant to current drugs. NovaBay 's in vitro and in vivo tests have demonstrated that our compounds kill a wide range of bacteria, viruses and other infection causing microbes, including those that are resistant to multiple antibiotics. The firm is developing hospital indications and has partnered certain other indications with Alcon, the world's leading eye care company, and with Galderma S.A., a global leading pharmaceutical company dedicated exclusively to the field of dermatology.